Chonnam medical journal最新文献_第10页

When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD? 在GOLD组B或D患者中，LABA/LAMA何时比LAMA更好地减少COPD的急性加重？

Chonnam medical journal Pub Date : 2023-09-01 Epub Date: 2023-09-25 DOI: 10.4068/cmj.2023.59.3.180

Hong-Joon Shin, Yu-Il Kim, Youlim Kim, Chang Youl Lee, Seung Won Ra, Ji-Yong Moon, Ki-Suck Jung, Kwang Ha Yoo, Kyeong-Cheol Shin, Sung-Chul Lim

{"title":"When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?","authors":"Hong-Joon Shin, Yu-Il Kim, Youlim Kim, Chang Youl Lee, Seung Won Ra, Ji-Yong Moon, Ki-Suck Jung, Kwang Ha Yoo, Kyeong-Cheol Shin, Sung-Chul Lim","doi":"10.4068/cmj.2023.59.3.180","DOIUrl":"10.4068/cmj.2023.59.3.180","url":null,"abstract":"Long-acting β2-agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual therapy has been found to be more effective than LAMA monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). However, among patients with group B or D COPD, the characteristics of patients for whom LABA/LAMA dual therapy is superior to LAMA monotherapy in minimizing acute exacerbations remain unknown. With data from a prospective COPD cohort, subgroup analyses were conducted to determine whether LABA/LAMA dual therapy was superior to LAMA monotherapy in reducing the rate of acute exacerbations in group B and D COPD patients. Group B and D COPD patients taking LAMA or LABA/LAMA were enrolled according to the 2022 Global initiative for Chronic Obstructive Pulmonary Disease guidelines. A total of 737 patients were included in this study: 600 with group B COPD and 137 with group D COPD. Compared with patients taking LAMA monotherapy, those taking LABA/LAMA had a significantly lower incidence of acute exacerbations over 1 year. In the subgroup of patients ≥70 years old, there was a significantly lower risk of severe COPD exacerbations among group B patients taking LABA/LAMA than among those taking LAMA monotherapy (odds ratio [OR], 0.258; 95% confidence interval [CI], 0.095-0.703). In contrast, in the subgroup of group D patients with COPD Assessment Test scores ≥25, compared with LAMA monotherapy, LABA/LAMA treatment was associated with lower risk of severe COPD exacerbations (OR, 0.115; 95% CI, 0.018-0.749). The combination of LABA and LAMA was found to be superior to LAMA monotherapy, especially for treating older adults with group B COPD, as well as for group D patients with severe symptoms.","PeriodicalId":94372,"journal":{"name":"Chonnam medical journal","volume":"59 3","pages":"180-187"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/24/cmj-59-180.PMC10570857.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overexpression of miR-146a and miR-155 are Potentially Biomarkers and Predict Unfavorable Relationship between Gastric Cancer and Helicobacter pylori Infection. miR-146a和miR-155的过度表达是潜在的生物标志物，可预测癌症与幽门螺杆菌感染之间的不利关系。

Chonnam medical journal Pub Date : 2023-09-01 Epub Date: 2023-09-25 DOI: 10.4068/cmj.2023.59.3.167

Masoud Karimi, Abdolreza Mohammadnia, Mohammad Amin Amini, Azar Ghavimi Shamekh, Elahe Derakhshanfar, Farzaneh Hosseini

{"title":"Overexpression of miR-146a and miR-155 are Potentially Biomarkers and Predict Unfavorable Relationship between Gastric Cancer and Helicobacter pylori Infection.","authors":"Masoud Karimi, Abdolreza Mohammadnia, Mohammad Amin Amini, Azar Ghavimi Shamekh, Elahe Derakhshanfar, Farzaneh Hosseini","doi":"10.4068/cmj.2023.59.3.167","DOIUrl":"10.4068/cmj.2023.59.3.167","url":null,"abstract":"Gastric Cancer (GC) is one of the most dangerous malignancies in the world. This study aims to evaluate the relationship between miR-146a and miR-155 in patients with H. pylori infections with GC compared to H. pylori-infected patients and healthy subjects. Forty patients with H. pylori and GC positive diagnoses and 40 patients with H. pylori positive and GC negative diagnoses, and 40 healthy persons were selected. The expression of miR-146a and miR-155 genes in the whole blood was examined using qRT-PCR. Moreover, ROC curves were drawn to represent the sensitivity and specificity of miR-146a and miR-155 expression as biomarkers. The results showed the expression of miR-146a and miR-155 in the whole blood of patients with H. pylori and GC positive diagnoses are significantly higher than in healthy individuals and are non-significantly enhanced compared to H. pylori positive and GC negative. Also, the results stated miR-146a and miR-155 expression in the whole blood of patients who are H. pylori positive and GC negative are significantly increased compared to healthy individuals. Furthermore, the ROC curve analysis of miR-146a and miR-155 RNA level demonstrated the two miRNAs have an appropriate sensitivity and specificity for diagnostic goals. In conclusion, H. pylori infection may increase the expression of miR-146a and miR-155 in patients with H. pylori and GC positive diagnoses, which can be effective in the curbing the progression of GC. For this reason, up-regulation of miR-146a and miR-155 along with H. pylori infection might contribute to the pathogenesis of GC, and also can be suggested as biomarkers for GC diagnosis and treatment.","PeriodicalId":94372,"journal":{"name":"Chonnam medical journal","volume":"59 3","pages":"167-173"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/97/cmj-59-167.PMC10570867.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coarctation of the Aorta. 主动脉缩窄。

Chonnam medical journal Pub Date : 2023-09-01 Epub Date: 2023-09-25 DOI: 10.4068/cmj.2023.59.3.202

Masatsugu Miyagawa, Daisuke Kitano, Yasuo Okumura

引用次数: 0

Primary Cardiac Angiosarcoma in a Patient with Syncope: A Case Report. 晕厥患者原发性心脏血管肉瘤1例报告。

Chonnam medical journal Pub Date : 2023-09-01 Epub Date: 2023-09-25 DOI: 10.4068/cmj.2023.59.3.211

Bo Eun Park, Dong Heon Yang, Se Yong Jang

引用次数: 0